Tissue Regenix Group PLC Distribution agreement for OrthoPure(R) XT in the UK (4187F)
July 10 2023 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 4187F
Tissue Regenix Group PLC
10 July 2023
Tissue Regenix Group plc
('Tissue Regenix', or the 'Company')
Multi-year distribution agreement for OrthoPure (R) XT signed in
the UK
Tissue Regenix (AIM: TRX), the regenerative medical device
company, announces that it has signed an exclusive distribution
agreement with Joint Operations Ltd ('Joint Operations'), a leading
distribution business in the UK supplying numerous products to
treat joint injuries and help to preserve the joints of the body,
for the
distribution of the Tissue Regenix OrthoPure(R) XT product in the United Kingdom.
The initial agreement is for three years, subject to annual
purchase minimums, and Joint Operations will add OrthoPure(R) XT to
its portfolio of products. Joint Operations already distributes
orthopaedic equipment to the National Health Service and the
private sector within the UK, offering clinicians comprehensive
orthopaedic solutions around joint reconstruction and preservation
surgeries.
The OrthoPure(R) XT decellularised xenograft ligament utilises
Tissue Regenix's patented dCELL(R) technology and is the only
available, non-human biologic graft for certain anterior cruciate
ligament ('ACL') reconstruction procedures on the market.
OrthoPure(R) XT can also be used in the reconstruction of other
knee ligaments, including multi-ligament and primary procedures
when an autograft is not an option.
Richard Forster, Managing Director of Joint Operations Ltd,
commented on the agreement: "We are delighted to be working with
Tissue Regenix to represent OrthoPure(R) XT in the UK. As a
company, we spend a great deal of time in ligament reconstructive
surgery, and it is tremendously exciting to have a unique xenograft
option to offer UK surgeons. In particular, we have been impressed
by the quality of clinical outcomes being achieved through the
Tissue Regenix clinical studies, and we look forward to these
results being replicated nationwide over the coming years."
Daniel Lee, Chief Executive Officer of Tissue Regenix, said: "We
are excited to partner with Joint Operations, who are experts in
the distribution of orthopaedic equipment within the UK where an
estimated 30,000 ACL surgeries take place each year(1) . This
strategic partnership will continue our reach into the UK, ensuring
these markets have access to our pioneering medical technology,
which will help to transform patient care."
(1) Beard, DJ. SNNAP Trial NDorms Oxford The Lancet, August
2022; https://www.ndorms.ox.ac.uk/news/ACL-SSNAP-trial-results
For more information:
Tissue Regenix Group plc www.tissueregenix.com
Daniel Lee, Chief Executive Officer via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR) Tel: +44 (0)20 7933 8780
Alice Woodings/Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical device company in
regenerative medicine. The Company's patented decellularisation
technology (dCELL(R)) removes DNA and other cellular material from
animal and human soft tissue, leaving an acellular tissue scaffold
not rejected by the patient's body that can be used to repair
diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R). This biotech company specialises in regenerative
medicine and is dedicated to developing high-quality, innovative
tissue scaffolds to enhance healing opportunities in defects
created by trauma and disease. CellRight's human tissue products
may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRRLMPTMTIMBFJ
(END) Dow Jones Newswires
July 10, 2023 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024